Merge Talks Between The EVERY Co and Onego Bio
Alt-egg startups The EVERY Company and Onego Bio were discussing a merger to create a new company with a valuation of $400m before talks fell apart.
According to court documents, the EVERY Co has urged a court in Wisconsin to dismiss a lawsuit from Onego Bio seeking to invalidate one of EVERY's patents.
Patent Dispute
The patent in question covers the production of ovalbumin, the primary protein in egg white, via precision fermentation.
- The EVERY Co uses yeast (Komagataella phaffii) as its host microorganism.
- Onego Bio uses fungus (Trichoderma reesei).
The dispute centers on whether Onego is infringing a “foundational” patent (‘784) from The EVERY Co covering ovalbumin expression in a range of hosts.
The EVERY Co has filed a legal document on October 28, revealing details of the talks and urging the court to toss the lawsuit.
Author's summary: Merger talks between The EVERY Co and Onego Bio failed, leading to a patent dispute.
More News
- Bam Adebayo's evolution into 'three-level scorer' starts with Heat's new offense
- Why Ryan Rollins loved Draymond Green coming for him after Stephen Curry incident
- Patriots' Rhamondre Stevenson is out for Sunday's game vs Falcons
- 'American Horror Story' Season 13 Features an A-List Actress & a Returning Legend
- Wemby’s Evolution Is Scary: Spurs Phenom Dominates Again, Leaves Heat Defenders Helpless
- Valley Stream woman charged after allegedly wrongfully receiving over $50,000 in SNAP benefits
- Stephen A. Smith Questions Why Chris Grier Got Fired Before Mike McDaniel After Dolphins' Embarrassing Loss
- Contractors fear retaliation if they try to recover shutdown costs
- 0-12? Stephen Curry Drops Truth Bomb On Steve Kerr's Declaration After Losing To Bucks Without Giannis
- Half of Illinois students reading at grade level, fewer in math under loosened standards